Goldman Sachs Group Inc. decreased its position in shares of Perrigo Company plc (NYSE:PRGO) by 5.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,090,031 shares of the company’s stock after selling 130,899 shares during the period. Goldman Sachs Group Inc.’s holdings in Perrigo were worth $182,166,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of PRGO. Crossmark Global Holdings Inc. acquired a new stake in shares of Perrigo during the 3rd quarter worth approximately $605,000. Canada Pension Plan Investment Board boosted its position in shares of Perrigo by 163.7% during the 3rd quarter. Canada Pension Plan Investment Board now owns 66,748 shares of the company’s stock worth $5,630,000 after acquiring an additional 41,438 shares in the last quarter. Andra AP fonden boosted its position in shares of Perrigo by 9.9% during the 3rd quarter. Andra AP fonden now owns 16,700 shares of the company’s stock worth $1,414,000 after acquiring an additional 1,500 shares in the last quarter. Chicago Equity Partners LLC acquired a new stake in shares of Perrigo during the 3rd quarter worth approximately $313,000. Finally, Swiss National Bank boosted its position in shares of Perrigo by 1.1% during the 3rd quarter. Swiss National Bank now owns 475,462 shares of the company’s stock worth $40,248,000 after acquiring an additional 5,400 shares in the last quarter. Institutional investors and hedge funds own 79.01% of the company’s stock.
Shares of Perrigo Company plc (PRGO) opened at $84.95 on Monday. The company has a quick ratio of 1.40, a current ratio of 1.96 and a debt-to-equity ratio of 0.53. The company has a market cap of $11,963.81, a price-to-earnings ratio of 17.20, a price-to-earnings-growth ratio of 1.96 and a beta of 0.82. Perrigo Company plc has a twelve month low of $63.68 and a twelve month high of $95.93.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 20th. Shareholders of record on Friday, March 2nd will be issued a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.89%. This is a boost from Perrigo’s previous quarterly dividend of $0.16. The ex-dividend date of this dividend is Thursday, March 1st. Perrigo’s dividend payout ratio (DPR) is presently 90.48%.
In other news, VP Todd W. Kingma sold 1,500 shares of Perrigo stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $88.52, for a total transaction of $132,780.00. Following the completion of the transaction, the vice president now directly owns 19,565 shares in the company, valued at $1,731,893.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Uwe Roehrhoff acquired 7,500 shares of Perrigo stock in a transaction dated Monday, March 5th. The shares were acquired at an average price of $81.85 per share, with a total value of $613,875.00. Following the completion of the acquisition, the chief executive officer now directly owns 4,900 shares of the company’s stock, valued at $401,065. The disclosure for this purchase can be found here. Company insiders own 6.90% of the company’s stock.
Several analysts recently issued reports on PRGO shares. Cantor Fitzgerald set a $107.00 price target on shares of Perrigo and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Barclays increased their price target on shares of Perrigo to $93.00 and gave the stock an “overweight” rating in a research report on Monday, December 4th. Argus upgraded shares of Perrigo from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a research report on Friday, December 8th. Canaccord Genuity set a $100.00 price target on shares of Perrigo and gave the stock a “buy” rating in a research report on Tuesday, December 26th. Finally, Leerink Swann started coverage on shares of Perrigo in a research note on Tuesday, January 2nd. They issued a “market perform” rating and a $90.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $91.88.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO).
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.